CSTL (Castle Biosciences) YoY EBITDA Growth: -23.42% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSTL Castle Biosciences Inc CSTL
82 GF Score
Price $34.25
GF Value $29.70
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Castle Biosciences YoY EBITDA Growth?

Castle Biosciences CSTL +3.92% 82 YoY EBITDA Growth is -23.42% as of Jun. 2026. GuruFocus rates CSTL with a GF Score™ of 82/100 and a GF Value™ of $29.70 (Modestly Overvalued). The stock has 4 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Castle Biosciences's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -23.42%.

Castle Biosciences's EBITDA per Share for the three months ended in Jun. 2026 was $0.09.

Castle Biosciences YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Castle Biosciences's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Castle Biosciences YoY EBITDA Growth Chart

Castle Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only -288.27 -53.78 24.97 177.62 -70.02

Castle Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -72.25 -70.90 -91.80 -381.30 -23.42
CSTL
82GF Score
Castle Biosciences Inc CSTL
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Castle Biosciences YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Castle Biosciences's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(0.391-1.304)/ | 1.304 |
=-70.02 %

Castle Biosciences's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(0.085-0.111)/ | 0.111 |
=-23.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -23.42% mean?
Castle Biosciences (CSTL) has a YoY EBITDA Growth of -23.42% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Castle Biosciences and its competitors.
Is Castle Biosciences' YoY EBITDA Growth too high?
Castle Biosciences' current YoY EBITDA Growth is -23.42%. Overall, Castle Biosciences has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' YoY EBITDA Growth compare to OPK and FLGT?
Castle Biosciences' YoY EBITDA Growth of -23.42% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Diagnostics & Research company?
A good YoY EBITDA Growth depends on the Medical Diagnostics & Research industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Castle Biosciences and its competitors. Castle Biosciences's current YoY EBITDA Growth is -23.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Overvalued. The stock's GF Value™ is $29.70, compared to a current price of $34.25 — trading 15.3% above its estimated fair value. The current YoY EBITDA Growth is -23.42%. Castle Biosciences' overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current YoY EBITDA Growth is -23.42% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Castle Biosciences (CSTL) Overvalued in 2026?

Based on GuruFocus' analysis, Castle Biosciences stock appears to be overvalued. The current stock price of $34.25 is trading 15.3% above its estimated GF Value™ of $29.70. GuruFocus considers Castle Biosciences to be Modestly Overvalued.

Key valuation signals for CSTL:

  • YoY EBITDA Growth: -23.42%
  • GF Value™: $29.70 vs. price of $34.25 (15.3% above fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Castle Biosciences Business Description

Other Exchanges 086:Germany
Address 1500 West Parkwood Avenue, Suite 401, Friendswood, TX, USA, 77546
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
82GF Score

Get the complete analysis for CSTL

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.25
Price
$29.70
GF Value